Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5170781 | 1.00 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL5169330 | 1.00 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL5646298 | 0.91 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL16893667 | 0.91 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL16893666 | 0.91 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL5646613 | 0.90 | PTGS2 (0.58) | PTGS2PTGS1 | |
| SCHEMBL16893763 | 0.90 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL16893766 | 0.90 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL5644727 | 0.89 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL5645332 | 0.89 | PTGS2 (0.55) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-1778662-A1 | PHOTORACEMIZATION OF 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1773802-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006011045-A1 | PHOTORACEMIZATION OF 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006011047-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006011052-A1 | METHOD FOR THE RACEMIZATION OF 2-TRIFLUORO-2H-CHROMENE-3-CARBOXYLIC ACIDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060020023-A1 | Racemization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| US-20060016683-A1 | Photoracamization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| US-20060020022-A1 | Enantioselective separation method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | NOS1, NOS2, NOS3 | PTGS2 608/4885PTGS1 209/4885 |
| US-20060020023-A1 | Racemization method | STS, SQLE, HAO2 | PTGS2 1102/4885PTGS1 1630/4885 |
| US-20060016683-A1 | Photoracamization method | CYP3A43, CRY2, CRY1 | PTGS2 728/4885PTGS1 1526/4885 |
| US-20060020022-A1 | Enantioselective separation method | SLC7A1, SLC10A1, DHCR7 | PTGS2 3281/4885PTGS1 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.